Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Juni 2018 16:00 ET | Quelle: Jounce Therapeutics, Inc.

Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers

CAMBRIDGE, Mass., June 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
30. Mai 2018 03:00 ET | Quelle: Helsinn Healthcare S.A.

Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f

Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid...
16. Mai 2018 17:01 ET | Quelle: Jounce Therapeutics, Inc.

Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting

ICONIC Target Enrollment Met Across Four Combination Cohorts Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Jounce...